Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBT Margin (2016 - 2025)

Historic EBT Margin for Ani Pharmaceuticals (ANIP) over the last 15 years, with Q3 2025 value amounting to 14.84%.

  • Ani Pharmaceuticals' EBT Margin rose 360700.0% to 14.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.11%, marking a year-over-year increase of 74600.0%. This contributed to the annual value of 3.62% for FY2024, which is 77000.0% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported EBT Margin of 14.84% as of Q3 2025, which was up 360700.0% from 4.98% recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' EBT Margin peaked at 18.43% during Q1 2024, and registered a low of 50.64% during Q4 2021.
  • For the 5-year period, Ani Pharmaceuticals' EBT Margin averaged around 8.05%, with its median value being 1.66% (2024).
  • As far as peak fluctuations go, Ani Pharmaceuticals' EBT Margin crashed by -465100bps in 2021, and later soared by 445600bps in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' EBT Margin (Quarter) stood at 50.64% in 2021, then soared by 88bps to 6.08% in 2022, then skyrocketed by 112bps to 0.72% in 2023, then tumbled by -1104bps to 7.22% in 2024, then soared by 305bps to 14.84% in 2025.
  • Its EBT Margin was 14.84% in Q3 2025, compared to 4.98% in Q2 2025 and 10.14% in Q1 2025.